It definitely looks like this run is not real based on the declining pps. Its a shame really because if they would have gotten the BARDA grant, the stock would have popped and there would be no need for a dilution. With covid, we will also likely get a 2 Q delay for the interim look which makes a significant dilution assured. This, coupled with management's silence, makes for a shaky picture at least in the short term.
Having said this, I still think Exebacase is a game changer but a big BARDA grant (which they deserve) is not in the cards cause of the pandemic.
News 
Market Data 
Discover 
